Matches in SemOpenAlex for { <https://semopenalex.org/work/W200584238> ?p ?o ?g. }
- W200584238 endingPage "71" @default.
- W200584238 startingPage "64" @default.
- W200584238 abstract "A prophylactic concept should be applied in cases of drug induced and conditions causing acute kidney injury which is a serious and common danger. Epidemiological studies concluded that smoking is an important remediable risk factor for development of acute and chronic kidney disease to end-stage renal disease. High-dose therapy with cisplatin which is a potent antitumor drug is limited by its cumulative nephrotoxicity and neurotoxicity. Exhaustive exercise or overload training causes histological changes in kidney cell manifesting as hematuria, proteinuria and acute renal failure. Exendin-4 (GLP-1 analogue) treatment effectively protected the kidney from injury in a rodent model of renal ischemia reperfusion injury through the suppression of inflammatory reaction, apoptosis and oxidative stress. The aim of this research is to clarify the protective effects of Exendin-4 on different causes of acute kidney injury of experimental animals and compare the injurious effect of nicotine, cisplatin and exhaustive exercise. Design: 70 healthy adult male albino rats were used to study the protective effect of Exendin-4 (administered at a dose of 25 nmol/kg in saline for 11 days) against injurious effect of nicotine bitartrate (at a dose of 200 μg/ml in a 2% saccharine solution as drinking source for 4 weeks), cisplatin (a single intraperitoneal injection at a dose of 7 mg/kg body weight) and exhaustive exercise for 4 weeks. Kidney injury was assessed by analysis of creatinine, BUN, serum KIM and urinary KIM. Results: The results of this study showed that in group IIb (Nicotine/Exendin-4 treated group) and group IVb (Exhaustive exercise/Exendin-4 treated group), the mean values were found to be significantly decreased when compared with non exendin treated groups. On comparing group IIIa (Cisplatin treated group) with that of both group IIa (Nicotine treated group) and group IVa (Exhaustive exercise group), it was found that the mean values were found to be significantly increased for all parameters. However, in group IIIb (Cisplatin/Exendin-4 treated group), the mean values were found to be non-significant for all test parameters when compared with that of group IIIa (Cisplatin treated group). Conclusion: It was observed that exendin-4 has a protective effect against kidney injury induced by nicotine and exhaustive exercise but not against cisplatin." @default.
- W200584238 created "2016-06-24" @default.
- W200584238 creator A5027330320 @default.
- W200584238 creator A5039019601 @default.
- W200584238 date "2014-01-01" @default.
- W200584238 modified "2023-09-24" @default.
- W200584238 title "Protective Effect of Exendin-4 (Glp-1 Analogue) in Acute Kidney Injury in Experimental Animals" @default.
- W200584238 cites W1860857195 @default.
- W200584238 cites W1964378492 @default.
- W200584238 cites W1964805401 @default.
- W200584238 cites W1973693892 @default.
- W200584238 cites W1981494429 @default.
- W200584238 cites W1997332398 @default.
- W200584238 cites W2010109515 @default.
- W200584238 cites W2010668503 @default.
- W200584238 cites W2019252988 @default.
- W200584238 cites W2049533913 @default.
- W200584238 cites W2051150238 @default.
- W200584238 cites W2053442494 @default.
- W200584238 cites W2054484970 @default.
- W200584238 cites W2054649558 @default.
- W200584238 cites W2064425521 @default.
- W200584238 cites W2066006564 @default.
- W200584238 cites W2068446361 @default.
- W200584238 cites W2086375815 @default.
- W200584238 cites W2090028514 @default.
- W200584238 cites W2096388283 @default.
- W200584238 cites W2099179668 @default.
- W200584238 cites W2099252920 @default.
- W200584238 cites W2100203899 @default.
- W200584238 cites W2100261879 @default.
- W200584238 cites W2102610155 @default.
- W200584238 cites W2102917327 @default.
- W200584238 cites W2104056775 @default.
- W200584238 cites W2109729849 @default.
- W200584238 cites W2111113242 @default.
- W200584238 cites W2114034590 @default.
- W200584238 cites W2114561453 @default.
- W200584238 cites W2115197476 @default.
- W200584238 cites W2116831537 @default.
- W200584238 cites W2121930621 @default.
- W200584238 cites W2126528640 @default.
- W200584238 cites W2131275386 @default.
- W200584238 cites W2145099862 @default.
- W200584238 cites W2146081758 @default.
- W200584238 cites W2147571221 @default.
- W200584238 cites W2148082038 @default.
- W200584238 cites W2153119343 @default.
- W200584238 cites W2153625048 @default.
- W200584238 cites W2159436931 @default.
- W200584238 cites W2160713807 @default.
- W200584238 cites W2162889276 @default.
- W200584238 cites W2168530522 @default.
- W200584238 cites W2515321369 @default.
- W200584238 hasPublicationYear "2014" @default.
- W200584238 type Work @default.
- W200584238 sameAs 200584238 @default.
- W200584238 citedByCount "1" @default.
- W200584238 countsByYear W2005842382016 @default.
- W200584238 crossrefType "journal-article" @default.
- W200584238 hasAuthorship W200584238A5027330320 @default.
- W200584238 hasAuthorship W200584238A5039019601 @default.
- W200584238 hasConcept C126189478 @default.
- W200584238 hasConcept C126322002 @default.
- W200584238 hasConcept C126894567 @default.
- W200584238 hasConcept C134018914 @default.
- W200584238 hasConcept C2776151105 @default.
- W200584238 hasConcept C2778653478 @default.
- W200584238 hasConcept C2779547902 @default.
- W200584238 hasConcept C2779561371 @default.
- W200584238 hasConcept C2780091579 @default.
- W200584238 hasConcept C2780159080 @default.
- W200584238 hasConcept C2780306776 @default.
- W200584238 hasConcept C2780472472 @default.
- W200584238 hasConcept C2781184683 @default.
- W200584238 hasConcept C555293320 @default.
- W200584238 hasConcept C71924100 @default.
- W200584238 hasConcept C98274493 @default.
- W200584238 hasConceptScore W200584238C126189478 @default.
- W200584238 hasConceptScore W200584238C126322002 @default.
- W200584238 hasConceptScore W200584238C126894567 @default.
- W200584238 hasConceptScore W200584238C134018914 @default.
- W200584238 hasConceptScore W200584238C2776151105 @default.
- W200584238 hasConceptScore W200584238C2778653478 @default.
- W200584238 hasConceptScore W200584238C2779547902 @default.
- W200584238 hasConceptScore W200584238C2779561371 @default.
- W200584238 hasConceptScore W200584238C2780091579 @default.
- W200584238 hasConceptScore W200584238C2780159080 @default.
- W200584238 hasConceptScore W200584238C2780306776 @default.
- W200584238 hasConceptScore W200584238C2780472472 @default.
- W200584238 hasConceptScore W200584238C2781184683 @default.
- W200584238 hasConceptScore W200584238C555293320 @default.
- W200584238 hasConceptScore W200584238C71924100 @default.
- W200584238 hasConceptScore W200584238C98274493 @default.
- W200584238 hasIssue "3" @default.
- W200584238 hasLocation W2005842381 @default.
- W200584238 hasOpenAccess W200584238 @default.
- W200584238 hasPrimaryLocation W2005842381 @default.